

CLAIMS

What is claimed is:

- 5 1. A composition for the treatment or prevention of
alveolar destruction in a mammal comprising a
pharmaceutically effective amount of an RAR β
antagonist having RAR specific modulating
activity.
- 10 2. The composition of claim 1 wherein said RAR β
antagonist is not specific to RAR α .
- 15 3. The composition of claim 1 wherein said RAR β
antagonist is not specific to RAR γ .
- 20 4. The composition of claim 1 wherein said RAR β
antagonist is not specific to RAR α or RAR γ .
- 25 5. The composition of claim 1 wherein said
composition further comprises said RAR β
antagonist in dissolved form.
6. The composition of claim 5 wherein said RAR β
antagonist is not specific to RAR α .
7. The composition of claim 5 wherein said RAR β
antagonist is not specific to RAR γ .

8. The composition of claim 5 wherein said RAR β antagonist is not specific to RAR α or RAR γ .
- 5 9. An aerosol for pulmonary delivery of a pharmaceutical composition, said pharmaceutical composition comprising an RAR β antagonist having specific RAR modulating activity.
- 10 10. The aerosol of claim 9 wherein said RAR β antagonist is not specific to RAR α .
11. The aerosol of claim 9 wherein said RAR β antagonist is not specific to RAR γ .
- 15 12. The aerosol of claim 9 wherein said RAR β antagonist is not specific to RAR α or RAR γ .
- 20 13. A method for the treatment or prevention of alveolar destruction in a mammal comprising the step of administering a therapeutically effective amount of an RAR β antagonist specific RAR modulating activity to said mammal.
- 25 14. The method of claim 13, wherein said RAR β antagonist is not specific to RAR α .
15. The method of claim 13 wherein said RAR β antagonist is not specific to RAR γ .

16. The method of claim 13 wherein said $\text{RAR}\beta$ antagonist is not specific to $\text{RAR}\alpha$ or $\text{RAR}\gamma$.
- 5 17. The method of claim 13, wherein said composition is administered in the form of an inhalant.
18. The method of claim 17 wherein said $\text{RAR}\beta$ antagonist is not specific to $\text{RAR}\alpha$.
- 10 19. The method of claim 17 wherein said $\text{RAR}\beta$ antagonist is not specific to $\text{RAR}\gamma$.
20. The method of claim 17 wherein said $\text{RAR}\beta$ antagonist is not specific to $\text{RAR}\alpha$ or $\text{RAR}\gamma$.
- 15 21. A method to increase the gas-exchange surface area of a mammalian lung in a mammal in need thereof comprising the step of administering a therapeutically effective amount of an $\text{RAR } \beta$ antagonist having specific RAR modulating activity to said mammal.
- 20 22. The method of claim 21, wherein said $\text{RAR}\beta$ antagonist is not specific to $\text{RAR}\alpha$.
- 25 23. The method of claim 21 wherein said $\text{RAR}\beta$ antagonist is not specific to $\text{RAR}\gamma$.

24. The method of claim 21 wherein said $RAR\beta$ antagonist is not specific to $RAR\alpha$ or $RAR\gamma$.

5 25. The method of claim 21, wherein said composition is administered in the form of an inhalant.


26. The method of claim 25 wherein said $RAR\beta$ antagonist is not specific to $RAR\alpha$.

10 27. The method of claim 25 wherein said $RAR\beta$ antagonist is not specific to $RAR\gamma$.

28. The method of claim 25 wherein said $RAR\beta$ antagonist is not specific to $RAR\alpha$ or $RAR\gamma$.

15

29. The $RAR\beta$ antagonist of any of the foregoing claims, comprising the structural formula:



20

wherein

- a) X is selected from the group consisting of CR_2 , O , S , and NR ;
- b) R' and R'' are each independently selected from the group consisting of H and lower alkyl;
- c) Ar and Ar' are each independently a single ring aryl moiety; and

25

- d) B is selected from the group consisting of --
CR'CH--,
--CHCR'--, --COO--, --OOC--; --COHN--; --NHOC--;
--CSHN--; and --NHSC--.

5

30. The RAR β antagonist of claim 29 wherein Ar
and Ar' are each independently selected from
the group consisting of substituted or
unsubstituted phenyl, furyl, thienyl and
pyridyl groups.

10